- The P-III AWARD-11 study results involve assessing of Trulicity (3.0mg/4.5mg, qw) vs Trulicity (1.5mg, qw) in 1842 patients with type 2 diabetes for 52wks.
- The P-III AWARD study resulted in meeting its 1EPs & 2EPs @36wks. i.e, superiority in A1C reduction & superiority on weight reduction with its expected completion in H2’19
- Trulicity is a therapy used to improve blood sugar level in type 2 diabetes mellitus in adults along with diet & exercise with its expected regulatory submission in H2’19
Click here to read full press release/ article | Ref: Eli Lilly | Image: Fortune